The type 2 diabetes medication Ozempic has been hugely popular when prescribed off-label for weight loss, thanks to its ability to regulate your blood sugar and curb your appetite. But between ...

Metformin is one of the most widely sold prescription drugs in the United States. Its main purpose is to improve insulin sensitivity and control blood glucose levels. But using Metformin for weight ...

Many newly diagnosed type 2 diabetes patients look for alternative ways to manage the chronic health issue, much like a Quora ...

Metformin is a trusted treatment for type 2 diabetes, but some people are being prescribed the drug for weight loss. (Getty Images) But what exactly does metformin do, and is it effective for weight ...

Whether you have type 2 diabetes, obesity or just a few extra pounds that you’d like some help shedding, chances are you’re one of the millions of adults worldwide who heard about Novo Nordisk’s ...

A drug usually prescribed for diabetes has been hailed as something akin to a miracle drug, but until now, scientists haven't ...

Treatment of gestational diabetes with metformin, and glyburide if needed, does not meet noninferiority criteria versus insulin. (HealthDay News) — With respect to the proportion of infants born large ...

Please provide your email address to receive an email when new articles are posted on . Women with gestational diabetes who received metformin had lower fasting glucose than those who received placebo ...

March 22, 2012 — Long-term treatment with metformin is safe for preventing or delaying the development of type 2 diabetes, according to an article published in the April issue of Diabetes Care. New ...

Drugs already taken by millions of diabetes patients appear to also help slash asthma attacks by up to 70%, new British research shows. The two drugs are metformin, one of the most widely used ...

Overall, 79% of the participants randomly assigned to oral agents maintained glycemic control without insulin. Doortje Rademaker, MD, from the Amsterdam University Medical Center, and colleagues ...